Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
SOUTH SAN FRANCISCO, Calif., July 26, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2017 financial results on Tuesday, August 8, 2017, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, August 8, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 61862496.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe Investor Relations 415-365-5737 [email protected]
